PFE - Pfizer Inc.
NEXT EARNINGS:
Apr 28, 2026
EPS Est: $0.73
|
Rev Est: $13.9B
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$27.50
DETAILS
HIGH:
$35.00
LOW:
$24.00
MEDIAN:
$27.00
CONSENSUS:
$27.50
UPSIDE:
2.69%
Market Cap:
152.28B
Volume:
29,576,037
Avg Volume:
44,796,359
52 Week Range:
20.92-27.94
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.41
Last Dividend:
$1.72
Exchange:
NYSE
Country:
US
Employees:
81,000
IPO Date:
1972-06-01
EPS (TTM):
1.36
P/E Ratio:
19.65
Revenue (TTM):
62.58B
Total Assets:
208.16B
Total Debt:
67.42B
Cash & Equiv:
1.14B
Rev Growth (5Y):
8.5%
EPS Growth (5Y):
-3.8%
FCF Growth (5Y):
-4.8%
ROCE:
6.0%
Debt/Equity:
0.78
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-03 | $0.66 | $0.57 | +16.4% | $17.6B | $16.8B | +4.2% |
| 2025-11-04 | $0.87 | $0.63 | +37.4% | $16.7B | $16.5B | +0.9% |
| 2025-08-05 | $0.78 | $0.58 | +34.5% | $14.7B | $13.6B | +8.1% |
| 2025-04-29 | $0.92 | $0.67 | +38.1% | $13.7B | $13.9B | -1.5% |
| 2025-02-04 | $0.63 | $0.47 | +33.6% | $17.8B | $17.4B | +2.4% |
| 2024-10-29 | $1.06 | $0.61 | +72.6% | $17.7B | $14.9B | +18.6% |
| 2024-07-30 | $0.60 | $0.46 | +31.0% | $13.3B | $13.0B | +2.5% |
| 2024-05-01 | $0.82 | $0.52 | +58.9% | $14.9B | $13.9B | +7.2% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.58B | 63.63B | 59.55B | 100.33B | 81.29B | 41.65B | 41.17B | 53.65B | 52.55B | 52.82B | 48.85B | 49.60B |
| Net Income | 7.77B | 8.02B | 2.13B | 31.36B | 22.15B | 9.16B | 16.27B | 11.15B | 21.30B | 7.21B | 6.97B | 9.08B |
| EPS | 1.36 | 1.42 | 0.38 | 5.59 | 3.95 | 1.65 | 2.92 | 1.90 | 3.57 | 1.18 | 1.13 | 1.43 |
| Total Assets | 208.16B | 213.40B | 226.50B | 197.21B | 181.48B | 154.23B | 167.49B | 159.42B | 171.80B | 171.62B | 167.46B | 169.27B |
| Total Debt | 67.42B | 66.99B | 70.84B | 34.86B | 37.00B | 38.27B | 50.84B | 41.74B | 42.61B | 41.06B | 38.90B | 36.68B |
| Cash & Equivalents | 1.14B | 1.04B | 2.85B | 416.00M | 1.94B | 1.79B | 1.12B | 1.14B | 1.34B | 2.60B | 3.64B | 3.34B |
| Operating Cash Flow | 11.71B | 12.74B | 8.70B | 29.27B | 32.58B | 14.40B | 12.59B | 15.83B | 16.47B | 15.90B | 14.51B | 16.88B |
| Free Cash Flow | 9.08B | 9.84B | 4.79B | 26.03B | 29.87B | 11.61B | 9.99B | 13.63B | 14.25B | 13.90B | 13.02B | 15.30B |
| FCF per Share | 1.60 | 1.74 | 0.85 | 4.64 | 5.33 | 2.09 | 1.79 | 2.32 | 2.39 | 2.28 | 2.11 | 2.41 |
| Book Value | 86.48B | 88.20B | 89.01B | 95.66B | 77.20B | 63.24B | 63.14B | 63.41B | 71.31B | 59.54B | 64.72B | 71.30B |
| Cash & ST Investments | 13.60B | 20.48B | 12.69B | 22.73B | 31.07B | 12.22B | 9.65B | 18.83B | 19.99B | 17.85B | 23.29B | 36.12B |
| ROC Equity | 0.09 | 0.09 | 0.02 | 0.33 | 0.29 | 0.14 | 0.26 | 0.18 | 0.30 | 0.12 | 0.11 | 0.13 |